Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Life Sciences
Variants In Wfs1 And Other Mendelian Deafness Genes Are Associated With Cisplatin-Associated Ototoxicity, Heather E. Wheeler, Eric R. Gamazon, Robert Frisina, Carlos Perez-Cervantes, Omar El Charif, Brandon Mapes, Sophie D. Fossa, Darren Feldman, Robert Hamilton, David J. Vaughn, Clair Beard, Chunkit Fung, Chiristian Kollmannsberger, Jeri Kim, Taisei Mushiroda, Michiaki Kubo, Shirin Ardeshir-Rouhani-Fard, Lawrence H. Einhorn, Nancy Cox, M. Eileen Dolan, Lois Travis
Variants In Wfs1 And Other Mendelian Deafness Genes Are Associated With Cisplatin-Associated Ototoxicity, Heather E. Wheeler, Eric R. Gamazon, Robert Frisina, Carlos Perez-Cervantes, Omar El Charif, Brandon Mapes, Sophie D. Fossa, Darren Feldman, Robert Hamilton, David J. Vaughn, Clair Beard, Chunkit Fung, Chiristian Kollmannsberger, Jeri Kim, Taisei Mushiroda, Michiaki Kubo, Shirin Ardeshir-Rouhani-Fard, Lawrence H. Einhorn, Nancy Cox, M. Eileen Dolan, Lois Travis
Bioinformatics Faculty Publications
Cisplatin is one of the most commonly used chemotherapy drugs worldwide and one of the most ototoxic. We sought to identify genetic variants that modulate cisplatin-associated ototoxicity (CAO). Experimental Design: We performed a genome-wide association study (GWAS) of CAO using quantitative audiometry (4-12 kHz) in 511 testicular cancer survivors of European genetic ancestry. We performed polygenic modeling and functional analyses using a variety of publicly available databases. We used an electronic health record cohort to replicate our top mechanistic finding. Results: One SNP, rs62283056, in the first intron of Mendelian deafness gene WFS1 (wolframin ER transmembrane glycoprotein) and an expression …
Comprehensive Audiometric Analysis Of Hearing Impairment And Tinnitus After Cisplatin-Based Chemotherapy In Survivors Of Adult-Onset Cancer., Robert D. Frisina, Heather E. Wheeler, Sophie D. Fossa, Sarah L. Kerns, Chunkit Fung, Howard D. Sesso, Patrick O. Monahan, Darren R. Feldman, Robert Hamilton, David J. Vaughn, Clair J. Beard, Amy Budnick, Eileen M. Johnson, Shirin Ardeshir-Rouhani-Fard, Lawrence H. Einhorn, Steven E. Lipshultz, M. Eileen Dolan, Lois B. Travis
Comprehensive Audiometric Analysis Of Hearing Impairment And Tinnitus After Cisplatin-Based Chemotherapy In Survivors Of Adult-Onset Cancer., Robert D. Frisina, Heather E. Wheeler, Sophie D. Fossa, Sarah L. Kerns, Chunkit Fung, Howard D. Sesso, Patrick O. Monahan, Darren R. Feldman, Robert Hamilton, David J. Vaughn, Clair J. Beard, Amy Budnick, Eileen M. Johnson, Shirin Ardeshir-Rouhani-Fard, Lawrence H. Einhorn, Steven E. Lipshultz, M. Eileen Dolan, Lois B. Travis
Bioinformatics Faculty Publications
PURPOSE:
Cisplatin is widely used but highly ototoxic. Effects of cumulative cisplatin dose on hearing loss have not been comprehensively evaluated in survivors of adult-onset cancer.
PATIENTS AND METHODS:
Comprehensive audiological measures were conducted on 488 North American male germ cell tumor (GCT) survivors in relation to cumulative cisplatin dose, including audiograms (0.25 to 12 kHz), tests of middle ear function, and tinnitus. American Speech-Language-Hearing Association criteria defined hearing loss severity. The geometric mean of hearing thresholds (0.25 to 12 kHz) summarized overall hearing status consistent with audiometric guidelines. Patients were sorted into quartiles of hearing thresholds of age- and …